| Applications: |
CLIA |
| Reactivity: |
Human |
| Note: |
FOR SCIENTIFIC EDUCATIONAL RESEARCH USE ONLY (RUO). MUST NOT BE USED IN DIAGNOSTIC OR OTHER MEDICAL APPLICATIONS. |
| Sensitivity: |
18.75pg/mL |
| Detection Limit: |
31.25~2000pg/mL |
| Short Description: |
This human TNFRSF11B kit is a highly sensitive in-vitro chemiluminescent immunoassay for the measurement of trace amounts of analytes. |
| Storage Instruction: |
If unopened the kit may be stored at 2-8°C for up to 1 month. If the kit will not be used within 1 month, store the components separately, according to the component table in the manual. |
| Assay Time: |
3.5h |
| Detection: |
Chemiluminescence |
| Gene Symbol: |
TNFRSF11B |
| Gene ID: |
4982 |
| Uniprot ID: |
TR11B_HUMAN |
| Specificity: |
This kit recognizes Human OPG in samples. No significant cross-reactivity or interference between Human OPG and analogues was observed. |
| Sample Type: |
Serum, plasma and other biological fluids |
| Tissue Specificity | Highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung. |
| Post Translational Modifications | N-glycosylated. Contains sialic acid residues. The N-terminus is blocked. |
| Function | Acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis. |
| Protein Name | Tumor Necrosis Factor Receptor Superfamily Member 11bOsteoclastogenesis Inhibitory FactorOsteoprotegerin |
| Database Links | Reactome: R-HSA-5669034 |
| Cellular Localisation | Secreted |
| Alternative CLIA Names | Tumor Necrosis Factor Receptor Superfamily Member 11b CLIA kitOsteoclastogenesis Inhibitory Factor CLIA kitOsteoprotegerin CLIA kitTNFRSF11B CLIA kitOCIF CLIA kitOPG CLIA kit |
| Specificity | This kit recognizes Human OPG in samples. No significant cross-reactivity or interference between Human OPG and analogues was observed. |
| Reproducibility | Both intra-CV and inter-CV are |
Information sourced from Uniprot.org
| Item | Specifications | Storage |
| Micro CLIA Plate (Dismountable) | 96T: 8 wells ×12 strips strips | -20℃, 6 months |
| Reference Standard | 96T: 2 vials 48T: 1 vial | -20℃, 6 months |
| Concentrated Biotinylated Detection Ab (100×) | 96T: 1 vial, 120 μL 60 μL | -20℃, 6 months |
| Concentrated HRP Conjugate (100×) | 96T: 1 vial, 120 μL 60 μL | -20℃ (Protect from light), 6 months |
| Reference Standard & Sample Diluent | 1 vial, 20 mL | 2-8°C, 6 months |
| Biotinylated Detection Ab Diluent | 1 vial, 14 mL | 2-8°C, 6 months |
| HRP Conjugate Diluent | 1 vial, 14 mL | 2-8°C, 6 months |
| Concentrated Wash Buffer (25×) | 1 vial, 30 mL | 2-8°C, 6 months |
| Substrate Reagent A | 1 vial, 5 mL | 2-8℃ (Protect from light) |
| Substrate Reagent B | 1 vial, 5 mL | 2-8℃ (Protect from light) |
| Plate Sealer | 5 pieces | |
| Manual | 1 copy | |
| Certificate of Analysis | 1 copy | |
| Sample Type | Range (%) | Average Recovery (%) |
| Serum(n=8) | 90-105 | 97 |
| EDTA plasma(n=8) | 87-101 | 94 |
| Cell culture media(n=8) | 86-98 | 93 |
| | Intra-assay Precision | Intra-assay Precision | Intra-assay Precision | Inter-assay Precision | Inter-assay Precision | Inter-assay Precision |
| Sample | 1.00 | 2.00 | 3.00 | 1.00 | 2.00 | 3.00 |
| n | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 |
| Mean (pg/mL) | 93.20 | 256.55 | 668.84 | 86.90 | 264.82 | 654.79 |
| Standard deviation | 9.78 | 28.78 | 58.26 | 9.19 | 20.13 | 67.51 |
| CV (%) | 10.49 | 11.22 | 8.71 | 10.58 | 7.60 | 10.31 |
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
